These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20438566)

  • 1. Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling.
    Moussa AS; Jones JS; Yu C; Fareed K; Kattan MW
    BJU Int; 2010 Nov; 106(9):1309-14. PubMed ID: 20438566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
    Yanke BV; Gonen M; Scardino PT; Kattan MW
    J Urol; 2005 Feb; 173(2):421-4. PubMed ID: 15643192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
    Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and external validation of an extended repeat biopsy nomogram.
    Chun FK; Briganti A; Graefen M; Porter C; Montorsi F; Haese A; Scattoni V; Borden L; Steuber T; Salonia A; Schlomm T; Latchemsetty K; Walz J; Kim J; Eichelberg C; Currlin E; Ahyai SA; Erbersdobler A; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
    J Urol; 2007 Feb; 177(2):510-5. PubMed ID: 17222622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and external validation of an extended 10-core biopsy nomogram.
    Chun FK; Briganti A; Graefen M; Montorsi F; Porter C; Scattoni V; Gallina A; Walz J; Haese A; Steuber T; Erbersdobler A; Schlomm T; Ahyai SA; Currlin E; Valiquette L; Heinzer H; Rigatti P; Huland H; Karakiewicz PI
    Eur Urol; 2007 Aug; 52(2):436-44. PubMed ID: 17010505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
    Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI
    BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
    Kawakami S; Koga F; Fujii Y; Saito K; Yamamoto S; Tatokoro M; Yonese J; Kageyama Y; Fukui I; Kihara K
    Int J Urol; 2008 Dec; 15(12):1055-60. PubMed ID: 19054174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presence of prostate cancer on saturation biopsy can be accurately predicted.
    Ahyai SA; Isbarn H; Karakiewicz PI; Chun FK; Reichert M; Walz J; Steuber T; Jeldres C; Schlomm T; Heinzer H; Salomon G; Budäus L; Perrotte P; Huland H; Graefen M; Haese A
    BJU Int; 2010 Mar; 105(5):636-41. PubMed ID: 20149204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
    Benecchi L; Pieri AM; Melissari M; Potenzoni M; Pastizzaro CD
    J Urol; 2008 Jul; 180(1):146-9. PubMed ID: 18485383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
    Walz J; Graefen M; Chun FK; Erbersdobler A; Haese A; Steuber T; Schlomm T; Huland H; Karakiewicz PI
    Eur Urol; 2006 Sep; 50(3):498-505. PubMed ID: 16631303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
    Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients.
    Suzuki H; Komiya A; Kamiya N; Imamoto T; Kawamura K; Miura J; Suzuki N; Nakatsu H; Hata A; Ichikawa T
    Urology; 2006 Jan; 67(1):131-6. PubMed ID: 16413348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PSA and its indices in determining the need for repeat prostate biopsies.
    Ukimura O; Durrani O; Babaian RJ
    Urology; 1997 Jul; 50(1):66-72. PubMed ID: 9218021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
    Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
    J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
    Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer.
    Svetec D; McCabe K; Peretsman S; Klein E; Levin H; Optenberg S; Thompson I
    J Urol; 1998 May; 159(5):1606-8. PubMed ID: 9554363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.